“…TDM of ISC is also recommended in subjects with severe hepatic impairment, as little is known about the drug pharmacokinetic properties in this group of patients (Desai, Schmitt-Hoffmann, Mujais, & Townsend, 2016;European Medicines Agency, 2015). Some analytical methods have been reported so far for the determination of ISC in human plasma and most of them employed mass spectrometry or fluorescence detection (Farowski et al, 2010;Fatiguso et al, 2017;Jørgensen, Andersen, Astvad, & Arendrup, 2017;McShane & Wang, 2017;Müller et al, 2017;Schmitt-Hoffmann, Roos, Maares, et al, 2006;Toussaint et al, 2017). Alternatively, a method based on ultra-performance liquid chromatography (UPLC) coupled with UV detection has also been developed (Verweij-van Wissen, Burger, Verweij, Aarnoutse, & Brüggemann, 2012).…”